Reducing Treatment Dose Errors with Low Molecular Weight Heparins
e.g. daltaparin,enoxaparin, tinzaparin,bemiparin (Fragmin,Clexane,Innohep,Zibor)
Full article from NSPA here http://www.nrls.npsa.nhs.uk/resources/?EntryId45=75208
Prescribed doses of low molecular weight heparins (LMWHs) for the treatment of a thromboembolic event are dependent on the weight of the patient and renal function. Underdosing has an increased risk of a further thromboembolic event, while overdosing can increase the risk of bleeding.
- Use the weight and renal function plus clinical indication as guide* to calculating the dose
- Record weight regularly if long term treatment and weight change (e.g. cancer)
- Essential information such as dose, weight, renal function, indication and duration of treatment must be communicated at transfers of care (e.g. by discharge letters) and used to ensure that future doses are safe
- As a GP, if in doubt, consult the specialist who initiated the treatment or a haematologist
(* this document p14-16 contains some examples of hospital regimes for DVT/PE )
|
